购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

RS 504393

Rating icon 很棒
产品编号 T5384Cas号 300816-15-3

RS 504393 是一种高度选择性的 CCR2 趋化因子受体拮抗剂,作用于人重组 CCR2 和 CCR1 受体,IC50值分别为 89 nM 和大于 100 μM。

RS 504393
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

RS 504393

Rating icon 很棒
纯度: 98.64%
产品编号 T5384Cas号 300816-15-3

RS 504393 是一种高度选择性的 CCR2 趋化因子受体拮抗剂,作用于人重组 CCR2 和 CCR1 受体,IC50值分别为 89 nM 和大于 100 μM。

规格价格库存数量
1 mg¥ 265现货
5 mg¥ 672现货
10 mg¥ 1,220现货
25 mg¥ 2,670现货
50 mg¥ 3,920现货
100 mg¥ 5,380现货
1 mL x 10 mM (in DMSO)¥ 739现货
大包装 & 定制
加入购物车
实验操作小课堂
常见问题解答
查看更多

"RS 504393"的相关化合物库

选择批次:
纯度:98.64%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
RS 504393 is a highly selective CCR2 chemokine receptor antagonist (IC50s: 89 nM and > 100 μM for human recombinant CCR2 and CCR1).
靶点活性
α1A-adrenoceptor:72 nM (cell free), CCR2:89 nM (cell free)
体外活性
RS-504393抑制了CCR2-CHL细胞中由MCP-1刺激的钙流入,其IC50值为35 nM [1]。作为CCR2的拮抗剂,RS 504393的处理显著抑制了过敏原诱导的β-己糖苷酶释放。这种抑制效果可通过补充重组MCP-1蛋白(100 pg/mL)[2]部分逆转。
体内活性
相较于接受了载体处理的小鼠明显展现出急性炎症迹象,RS 504393处理的小鼠却未表现出即时过敏的临床迹象。在天真(naive)动物中未观察到任何效果。RS 504393处理的小鼠中肥大细胞的脱颗粒作用显著受到抑制,但对天真小鼠无影响[2]。与CCR2缺陷小鼠所获得的结果类似,RS-504393的治疗显著减轻了肾脏病理变化,特别是通过减少I型胶原蛋白合成介导的广泛间质纤维化[3]。
激酶实验
Briefly, binding was measured using membranes prepared from two cell lines, THP-1 and CCR2-CHL cells. Each competition assay was composed of cell membranes, 50 pM 125I-MCP, MCP buffer, protease inhibitors, and test compound. Equilibrium was achieved by incubation at 28?°C for 90 min. Membrane-bound 125I-MCP was collected by filtration through GF/B filters presoaked in polyethyleneimine and bovine serum albumin, followed by four rapid washes with approximately 0.5 ml of ice-cold buffer containing 0.5 M NaCl and 10 mM HEPES, pH 7.4. MCP buffer consists of 50 mMHEPES, pH 7.2, 1 mM CaCl2, 5 mMMgCl2, and 0.1% bovine serum albumin. Protease inhibitors include 0.1 mM phenylmethylsulfonyl fluoride, 1 μM leupeptin, and 0.35 mg/ml pepstatin. THP-1 cells are a human monocyte cell line that express both CCR1 and CCR2. CCR2-CHL cells are Chinese hamster lung cells that have been stably transformed with an expression vector bearing the human CCR2b receptor [1].
细胞实验
Briefly, cytosolic calcium influx was measured in CCR2-CHL cells loaded with the fluorescent dye Fura-2-AM. Quantitation of signal intensity used the integrated signal intensity for 82 s after the addition of chemokine and thus has units of M·s. Antagonism by various compounds of calcium influx was measured using an approximate ED50 dose of MCP-1 (3 nM) and an approximate ED25 dose for MCP-3 (5 nM). Chemotaxis was measured over 1 h using THP-1–5X cells in a 96-well Boyden chamber apparatus. Cell migration through the polycarbonate filter was quantified by fluorescent staining using propidium iodide in 0.1% Triton X-100. These assays typically gave stimulated to unstimulated migration of 6-fold, range 4–10-fold, using a maximally effective concentration of MCP-1. Chemotaxis antagonist measurements used 3 nM MCP-1 or RANTES; these concentrations are near the ED95 attractant concentration for MCP-1 and for RANTES as agonists. The data are expressed by normalization to the uninhibited migration caused by the agonist chemokine. The antagonist was present in both chambers of the Boyden apparatus [1].
动物实验
To evaluate the therapeutic effects of MCP-1/CCR2 signaling, either propagermanium (3 or 8 mg/kg orally once a day) or RS-504393 (2 mg/kg orally twice a day) was mandatorily injected into their mouths to wild-type mice from 3 days before ureteral ligation until the day of sacrifice. In addition, to determine the viability for the usage of CCR2 antagonists for the treatment of renal fibrosis, propagermanium (8 mg/kg) was given daily, beginning 4 days after ureter ligation. For pathological examination, both the obstructed and contralateral kidneys were harvested from UUO animals 4, 7, and 14 days after ureteral ligation (n = 5 at each time point). Untreated age-matched male wild-type mice and CCR2-deficient mice were used as normal control (n = 6 for each group). Since propagermanium treatment was started from 3 days before ureteral ligation, mice treated with propagermanium for 3 days at day 0 were used as a negative control (n = 5) [3].
化学信息
分子量417.5
分子式C25H27N3O3
CAS No.300816-15-3
SmilesCc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1
密度1.282g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 10 mg/mL (23.95 mM)
H2O: Insoluble
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM2.3952 mL11.9760 mL23.9521 mL119.7605 mL
5 mM0.4790 mL2.3952 mL4.7904 mL23.9521 mL
10 mM0.2395 mL1.1976 mL2.3952 mL11.9760 mL
20 mM0.1198 mL0.5988 mL1.1976 mL5.9880 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy RS 504393 | purchase RS 504393 | RS 504393 cost | order RS 504393 | RS 504393 chemical structure | RS 504393 in vivo | RS 504393 in vitro | RS 504393 formula | RS 504393 molecular weight